Clinical research progress of tumor mutational burden in<em>EGFR</em>-mutant advanced non-small cell lung cancer

何　夕; 焦晓栋; 臧远胜

doi:10.19401/j.cnki.1007-3639.2021.01.009

您当前的位置：

首页 >

文章列表页 >

Clinical research progress of tumor mutational burden inEGFR-mutant advanced non-small cell lung cancer

更新时间：2026-01-27

- Clinical research progress of tumor mutational burden inEGFR-mutant advanced non-small cell lung cancer
- China Oncology Vol. 31, Issue 1, Pages: 69-75(2021)
- 作者机构：
  
  海军军医大学附属长征医院肿瘤科,上海,200433
- 作者简介：
- 基金信息：
- DOI：10.19401/j.cnki.1007-3639.2021.01.009
  CLC： R734.2
- Published Online：22 February 2021，
  
  Published：22 February 2021
- 稿件说明：
移动端阅览
何　夕, 焦晓栋, 臧远胜. 肿瘤突变负荷在

何　夕, 焦晓栋, 臧远胜. Clinical research progress of tumor mutational burden inEGFR-mutant advanced non-small cell lung cancer[J]. China Oncology, 2021, 31(1): 69-75.
何　夕, 焦晓栋, 臧远胜. 肿瘤突变负荷在 DOI： 10.19401/j.cnki.1007-3639.2021.01.009.

何　夕, 焦晓栋, 臧远胜. Clinical research progress of tumor mutational burden inEGFR-mutant advanced non-small cell lung cancer[J]. China Oncology, 2021, 31(1): 69-75. DOI： 10.19401/j.cnki.1007-3639.2021.01.009.

摘要

表皮生长因子受体（epidermal growth factor receptor，EGFR）-酪氨酸激酶抑制剂（tyrosine kinase inhibitor，TKI）的应用使EGFR突变型非小细胞肺癌（non-small cell lung cancer，NSCLC）患者的生存显著改善，但仍有部分患者疗效及预后不佳，寻求预测此类患者疗效及预后的标志物迫在眉睫。肿瘤突变负荷（tumor mutational burden，TMB）前期主要应用于免疫治疗获益人群的筛选及疗效预测，近期在EGFR突变型NSCLC中也有相应的探索性研究。就TMB的检测与挑战及其在EGFR突变型晚期NSCLC中的最新应用研究进展进行综述。

Abstract

The application of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) has significantly improved the survival of patients with EGFR-mutant non-small cell lung cancer (NSCLC). However

there are still a portion of patients with poor efficacy and prognosis. Therefore

it is urgently needed to find effective emerging prognostic markers. In the past few years

tumor mutational burden (TMB) was mainly used to screen patients who benefitted from immunotherapy and predict the efficacy. Recently

there are also corresponding exploratory studies on EGFR-mutant NSCLC. In this review

we summarized the challenges of TMB test and latest clinical research in EGFR-mutant advanced NSCLC.

关键词

Keywords

references

Views

2589

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer

The resistance mechanism and coping strategy of the third-generation EGFR-TKIs in NSCLC

NRP1 expression is associated with chemosensitivity and poor prognosis in advanced non-small cell lung cancer patients treated with first-line platinum-based chemotherapy

Detection of EGFR gene mutations with mutation-specific immunohistochemistry in non-small cell lung cancer

Correlation between δ-catenin and Cdc42 expression in non-small cell lung cancer

Related Author

申宇嘉

傅小龙

秦闪闪

常建华

冯卫能

张良运

石海燕

张龙富

Related Institution

上海交通大学附属胸科医院放疗科

上海交通大学医学院

复旦大学附属肿瘤医院肿瘤内科，复旦大学上海医学院肿瘤学系

佛山市第一人民医院头颈胸肿瘤内科

佛山市第一人民医院病理科

AI问答

⁰

Clinical research progress of tumor mutational burden inEGFR-mutant advanced non-small cell lung cancer

DOI：10.19401/j.cnki.1007-3639.2021.01.009

摘要

Abstract

关键词

Keywords

references